TRILLIUM THERAPEUTICS INC. 10,000,000 Common Shares UNDERWRITING AGREEMENTUnderwriting Agreement • September 11th, 2020 • Trillium Therapeutics Inc. • Pharmaceutical preparations • New York
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • September 9th, 2020 • Trillium Therapeutics Inc. • Pharmaceutical preparations • New York
This Securities Purchase Agreement (this "Agreement") is dated as of September 8, 2020, between Trillium Therapeutics Inc., a corporation organized under the laws of the Province of British Columbia (the "Company"), and Pfizer Inc., a corporation organized under the laws of the State of Delaware (the "Purchaser").
EXECUTIVE EMPLOYMENT AGREEMENT made as of February 11, 2016 Between TRILLIUM THERAPEUTICS INC. (hereinafter called the "Corporation") - and – DR. NICLAS STIERNHOLM (hereinafter called the "Executive")Executive Employment Agreement • April 21st, 2016 • Trillium Therapeutics Inc. • Pharmaceutical preparations • Ontario
AND WHEREAS the Corporation has provided the Executive with an increase in potential change in control entitlements as valuable consideration for the amendments;
PFIZER INC. - and - PF ARGENTUM ACQUISITION ULC - and - TRILLIUM THERAPEUTICS INC. ARRANGEMENT AGREEMENT August 20, 2021Arrangement Agreement • August 23rd, 2021 • Trillium Therapeutics Inc. • Pharmaceutical preparations • British Columbia
NOW THEREFORE, in consideration of the covenants and agreements herein contained and other good and valuable consideration (the receipt and sufficiency of which are hereby acknowledged), the Parties agree as follows:
TRILLIUM THERAPEUTICS INC. $25,000,000 Common Shares SALES AGREEMENTSales Agreement • June 20th, 2018 • Trillium Therapeutics Inc. • Pharmaceutical preparations • New York
Trillium Therapeutics Inc., a corporation organized under the laws of the Province of Ontario, Canada (the “Company”), confirms its agreement (this “Agreement”) with Cowen and Company, LLC (“Cowen”), as follows:
EXECUTIVE EMPLOYMENT AGREEMENT made as of February 11, 2016 Between TRILLIUM THERAPEUTICS INC. (hereinafter called the "Corporation") - and – DR. ROBERT UGER (hereinafter called the "Executive")Executive Employment Agreement • April 21st, 2016 • Trillium Therapeutics Inc. • Pharmaceutical preparations • Ontario
AND WHEREAS the Corporation has provided the Executive with an increase in termination entitlements as valuable consideration for the amendments
RIGHTS AGREEMENT DATED AS OF September 16, 2013 as amended on June 3, 2014 between TRILLIUM THERAPEUTICS INC. (formerly, Stem Cell Therapeutics Corp.) and COMPUTERSHARE INVESTOR SERVICES INC. as Rights AgentRights Agreement • August 12th, 2014 • Trillium Therapeutics Inc. • Ontario
The undersigned hereby irrevocably elects to exercise ________________ whole Rights represented by the attached Rights Certificate to purchase the Shares issuable upon the exercise of such Rights and requests that certificates for such Shares be issued in the name of:
EMPLOYMENT AGREEMENTEmployment Agreement • May 7th, 2021 • Trillium Therapeutics Inc. • Pharmaceutical preparations • Massachusetts
THIS EMPLOYMENT AGREEMENT (“Agreement”), effective April 26, 2021 (“Effective Date”), is made between Trillium Therapeutics USA Inc., a Delaware corporation (“Employer” or the “Company”), and Benjamin Looker, Esq. (“Employee”). Employee and the Company are sometimes referred to herein as the “Parties” and individually as a “Party.”
Confidential treatment has been requested for portions of this exhibit. The copy filed herewith omits the information subject to the confidentiality request. Omissions are designated as [***]. A complete version of this exhibit has been filed...Line Sale Agreement • October 3rd, 2014 • Trillium Therapeutics Inc. • Pharmaceutical preparations • New Jersey
This GPEx®-Derived Cell Line Sale Agreement (this “Agreement”) is made as of this 11th day of August, 2014 (“Effective Date”), by and between Trillium Therapeutics Inc., an Ontario corporation, with a place of business at 96 Skyway Avenue, Toronto, Ontario M9W, 4Y9, Canada (“Client”), and Catalent Pharma Solutions, LLC, a Delaware limited liability company, with a place of business at 14 Schoolhouse Road, Somerset, New Jersey 08873, USA (“Catalent”).
TRILLIUM THERAPEUTICS INC. 35,731,818 Common Shares 1,250,000 Series II Non- Voting Convertible First Preferred Shares UNDERWRITING AGREEMENTUnderwriting Agreement • January 23rd, 2020 • Trillium Therapeutics Inc. • Pharmaceutical preparations • New York
EMPLOYMENT AGREEMENTEmployment Agreement • March 11th, 2019 • Trillium Therapeutics Inc. • Pharmaceutical preparations • Massachusetts
THIS EMPLOYMENT AGREEMENT (“Agreement”), effective April 23, 2018 (“Effective Date”), is made between Trillium Therapeutics USA Inc., a Delaware corporation (“Employer” or the “Company”), and Dr. Yaping Shou (“Employee”). Employee and the Company are sometimes referred to herein as the “Parties.”
EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • March 31st, 2015 • Trillium Therapeutics Inc. • Pharmaceutical preparations • Washington
THIS EXECUTIVE EMPLOYMENT AGREEMENT (“Agreement”), effective April 1, 2015 (“Effective Date”), is made between Trillium Therapeutics USA Inc., a Delaware corporation (“Employer” or the “Company”), a subsidiary of Trillium Therapeutics Inc. (the “Parent Company”) and Eric L. Sievers (“Executive”). Executive and the Company are sometimes referred to herein as the “Parties.”
INDEMNITY AGREEMENTIndemnity Agreement • March 18th, 2021 • Trillium Therapeutics Inc. • Pharmaceutical preparations • Ontario
THIS INDENTURE made this 26th day of May, 2015. IN PURSUANCE OF THE SHORT FORMS OF LEASES ACT BETWEEN: PENWEST REVENUE CORP. herein called the “Landlord”Indenture • March 18th, 2021 • Trillium Therapeutics Inc. • Pharmaceutical preparations • Ontario
SUBSCRIPTION AGREEMENT (NON-BROKERED)Subscription Agreement • November 15th, 2017 • Trillium Therapeutics Inc. • Pharmaceutical preparations • New York
The undersigned (the “Subscriber”) hereby irrevocably subscribes for, and the Company hereby irrevocably accepts the subscription by the Subscriber for, the number of common shares (“Common Shares”) and/or Series 2 non-voting convertible first preferred shares (“Preferred Shares”) of the Company (collectively, the “Shares”) for the aggregate subscription price set forth below, representing a subscription price of US$8.50 per Common Share and US$8.50 per Preferred Share, upon and subject to the terms and conditions set forth in this Subscription Agreement, including the “Terms of Offering” attached hereto. In addition to this face page, the Subscriber must also complete all applicable schedules attached hereto.
January 3, 2019 PPF OFF 100 Cambridge Park Drive, LLC c/o Morgan Stanley Real Estate Advisor, Inc. New York, New York 10036 Attention: Jennie Pries Friend VIA Courier Re: Trillium Therapeutics USA Inc. and PPF PFF 100 Cambridge Park Drive, LLC Lease...Lease Agreement • March 18th, 2021 • Trillium Therapeutics Inc. • Pharmaceutical preparations • Massachusetts
This Lease Agreement (this "Lease") is made and entered into as of the 10th day of December, 2018 (the "Effective Date"), by and between PPF OFF 100 CAMBRIDGE PARK DRIVE, LLC, a Delaware limited liability company ("Landlord") and TRILLIUM THERAPEUTICS USA INC., a Delaware corporation ("Tenant").
VOTING SUPPORT AGREEMENTVoting Support Agreement • August 23rd, 2021 • Trillium Therapeutics Inc. • Pharmaceutical preparations • Ontario
NOW THEREFORE, in consideration of the mutual covenants and agreements set forth in this Agreement, and for other good and valuable consideration (the receipt and sufficiency of which are hereby acknowledged), the Parties hereby agree as follows:
TRILLIUM THERAPEUTICS INC. 2,750,000 Common Shares 3,250,000 Series II First Preferred Shares UNDERWRITING AGREEMENTUnderwriting Agreement • May 26th, 2017 • Trillium Therapeutics Inc. • Pharmaceutical preparations • New York
Trillium Therapeutics Inc., a corporation organized under the laws of the Province of Ontario, Canada (the “Company”), confirms its agreement with Cowen and Company, LLC (“Cowen”) and each of the other Underwriters named in Schedule A hereto (collectively, the “Underwriters,” which term shall also include any underwriter substituted as hereinafter provided in Section 10 hereof), for whom Cowen is acting as representative (in such capacity, the “Representative”), with respect to (i) the sale by the Company and the purchase by the Underwriters, acting severally and not jointly, of the respective numbers of common shares, no par value per share, of the Company (“Common Shares”) and Series II Non-Voting Convertible First Preferred Shares, no par value (the “Series II First Preferred Shares”) set forth in Schedule A hereto and (ii) the grant by the Company to the Underwriters, acting severally and not jointly, of the option described in Section 2(b) hereof to purchase all or any part of 412
SUBSCRIPTION AGREEMENTAgreement • March 31st, 2015 • Trillium Therapeutics Inc. • Pharmaceutical preparations • Ontario
THESE SECURITIES HAVE NOT BEEN REGISTERED UNDER THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED, OR STATE LAWS, AND MAY NOT BE OFFERED FOR SALE IN THE UNITED STATES UNLESS EXEMPT THEREUNDER FROM SUCH REGISTRATION.
TRILLIUM THERAPEUTICS INC. US$50,000,000 Common Shares SALES AGREEMENTTrillium Therapeutics Inc. • May 5th, 2020 • Pharmaceutical preparations • New York
Trillium Therapeutics Inc., a corporation organized under the laws of the Province of British Columbia, Canada (the "Company"), confirms its agreement (this "Agreement") with Evercore Group L.L.C. ("Evercore"), as follows:
AMENDED & RESTATED LICENSE AGREEMENTLicense Agreement • August 12th, 2014 • Trillium Therapeutics Inc. • Ontario
This amended and restated second license agreement (“Agreement”, as further defined herein) is made effective as of February 1st, 2010 (the "Effective Date"), and is amended as of June 1, 2012 (the “Amendment Date”), and is between:
SECOND AMENDED & RESTATED LICENSE AGREEMENTLicense Agreement • March 11th, 2019 • Trillium Therapeutics Inc. • Pharmaceutical preparations • Ontario
This second amended and restated license agreement (“Agreement”, as further defined herein) is amended as of May 31, 2018 (“Execution Date”) and made effective as of February 1, 2010 (the "Effective Date") unless otherwise noted, and is between:
TRILLIUM THERAPEUTICS INC. 6,550,000 Common Share Units 12,200,000 Series II Non-Voting Convertible First Preferred Share Units UNDERWRITING AGREEMENTUnderwriting Agreement • February 25th, 2019 • Trillium Therapeutics Inc. • Pharmaceutical preparations • New York
SHARE PURCHASE AGREEMENT among: TRILLIUM THERAPEUTICS INC., an Ontario corporation FLUORINOV PHARMA INC., an Ontario corporation and the SHAREHOLDERSShare Purchase Agreement • February 5th, 2016 • Trillium Therapeutics Inc. • Pharmaceutical preparations • Ontario
THIS SHARE PURCHASE AGREEMENT (the "Agreement") is made and entered into as of January 26, 2016, by and among: TRILLIUM THERAPEUTICS INC., an Ontario corporation ("Purchaser"); FLUORINOV PHARMA INC., an Ontario corporation (the "Company"); and each of the shareholders of the Company listed on the signature pages hereto (the "Shareholders"). Certain other capitalized terms used in this Agreement are defined in Exhibit A.
ROYALTY AGREEMENT among: TRILLIUM THERAPEUTICS INC., an Ontario corporation; FLUORINOV PHARMA INC., an Ontario corporation; and the SHAREHOLDERS Dated as of January 26, 2016Royalty Agreement • February 5th, 2016 • Trillium Therapeutics Inc. • Pharmaceutical preparations • Ontario
THIS ROYALTY AGREEMENT (the "Agreement") is made and entered into as of January 26, 2016, by and among: TRILLIUM THERAPEUTICS INC., an Ontario corporation ("Purchaser"); FLUORINOV PHARMA INC., an Ontario corporation (the "Company"); and each of the shareholders of the Company listed on the signature pages hereto (the "Shareholders"). Certain other capitalized terms used in this Agreement are defined in Exhibit A.
AGENCY AGREEMENTAgency Agreement • August 12th, 2014 • Trillium Therapeutics Inc. • Ontario
DEBENTURE PURCHASE AGREEMENT AND MERGER AGREEMENT AMONG STEM CELL THERAPEUTICS CORP. - and - 2364556 ONTARIO INC. - and - TRILLIUM THERAPEUTICS INC. - and - COVINGTON FUND II INC. - and - GROWTHWORKS CANADIAN FUND LTD. - and - BDC CAPITAL INC. - and -...Debenture Purchase Agreement • August 12th, 2014 • Trillium Therapeutics Inc. • Ontario
HEPARIN BINDING MITOGEN WITH HOMOLOGY TO EPIDERMAL GROWTH FACTOR (EGF) TTI-14-US Children's Medical Center Corp./Scios Nova Klagsrun, Abraham, Higashiyama, Besner 08/039364 10/16/91 5811393 09/22/98
